// Contents

In 2023, a Swiss lab sat diabetic mice belly-down on a loudspeaker and played them Queen’s “We Will Rock You.” Each mouse carried a capsule of engineered cells under its skin, and the cells released insulin when the bass hit. It worked, but only while the mouse stayed on the speaker. In a “mouse disco,” where the animals roamed freely, the music switched nothing on.

Three years later, the same lab (Martin Fussenegger’s group at ETH Zurich, based in Basel) has stripped everything alive out of the implant. The new device is smaller than a matchbox: a scrap of graphite felt studded with gold and platinum, some electronics and a wireless power receiver. Once switched on, it oxidizes excess blood sugar into gluconate, which the kidneys flush out in urine. In effect, it is the lab’s own sugar fuel cell run in reverse: instead of pulling electricity out of sugar, it spends electricity to burn sugar off. In mice with type 2 diabetes, blood sugar returned to normal in about an hour. Over six weeks, the animals lost up to 10% of their body weight while eating just as much as before. The work appeared in Science on October 22, 2026. Nobody has tested it in a human yet.

The stakes are large. By the authors’ count, type 2 diabetes and the obesity that usually travels with it (a pair they call “diabesity”) affect more than 2.5 billion people and cost health systems close to $3 trillion a year. Doctors treat it today with insulin and GLP-1 injections, and both need careful dosing.

The cells that listened to Queen

For years, Fussenegger’s lab has built “designer cells”: ordinary human cells fitted with a genetic circuit that makes a useful protein when an outside signal arrives. For diabetes, it has tried some unlikely triggers.

// Timeline

  1. Capsules of cells under the skin of mice respond to the caffeine in a cup of coffee by releasing GLP-1, a hormone that prompts the body to make insulin. The study ran in Nature Communications.
  2. An implant slightly bigger than a thumbnail, shaped like a tea bag, harvests electricity from glucose and uses it to wake up artificial beta cells.
  3. Cells respond to direct current: once a day, acupuncture needles charged to 4.5 volts touch the skin for 10 seconds, and blood sugar in mice with type 1 diabetes goes back to normal.
  4. Cells release insulin to music: “We Will Rock You” triggers 70% of the response within 5 minutes and all of it within 15.
  5. An implant with no cells, enzymes or drugs: just a catalyst and electronics.

The ingenuity is real. The pharmacy is still far away. In 2023, Fussenegger was blunt about the sugar-powered tea bag: bringing such a device to market, he said, was “far beyond our financial and human resources.” Living parts are fussy, too. The immune system may attack foreign cells, the cells themselves are unstable and hard to make consistently, and regulators approach them warily.

The lab used to wake its cells with music, caffeine and current
The lab used to wake its cells with music, caffeine and current

A fuel cell run in reverse

“For decades, we have treated diabetes by telling the body how to manage glucose,” Fussenegger says in the ETH press release on the new work. “We are now showing that we can take control of glucose directly, using electronics rather than drugs.”

The chemistry is nearly the same as in the 2023 tea bag. Back then, copper-based nanoparticles split glucose into gluconic acid and pulled electricity out of the reaction. Sugar was the fuel, electricity was the prize, and the cells still did the actual treating.

Now the setup is flipped. Power comes from outside, beamed in wirelessly: 0.75 volts (half an AA battery) at 13.56 megahertz. Contactless bank cards and phone NFC use the same frequency, a standard band also set aside for medical equipment. Under an electron microscope, the catalyst looks like a scatter of “desert roses”: little balls of tiny gold platelets “dusted” with platinum, sitting on porous graphite. It uses the incoming energy to oxidize glucose in the fluid around the cells. Put simply, it burns sugar not for energy but to get rid of it. What is left is gluconate, which the kidneys know how to clear.

That is a real break from the usual treatment. Insulin brings sugar down but does nothing about the energy surplus: glucose the body does not spend gets stored as fat. The catalyst removes it before it gets that far.

The cue to switch on comes from an off-the-shelf glucose sensor, the kind people wear on the upper arm. It sends readings to a smartphone, which turns the implant on when sugar runs high and off once it is back in range. Fussenegger says the catalyst activates only when glucose is too high, and the team saw no hypoglycemia (a dangerous drop in blood sugar) in the mice. The fully automatic setup ran for two weeks in eight mice.

The mice lost weight on the same diet

In the main experiment, the implant ran for one hour a day. For six weeks, the mice kept normal blood sugar, lost up to 10% of their weight and had lower triglycerides (fats in the blood). Free fatty acids and ketone bodies went up, a sign that the body had started burning stored fat instead of sugar. They ate as much as ever.

When the authors examined the animals afterward, they found no signs of electrical or heat damage to tissue, no inflammation and no odd behavior. The catalyst could still oxidize glucose after up to three months under the skin, though nobody yet knows how long the whole device would last.

Fussenegger argues that the system goes after the root of the disease: the surplus energy glucose brings into the body. He then goes further. If the device proves safe, he suggests, it could also help people without diabetes lose weight. For now that is the inventor’s view, with no data behind it.

A mouse eats about 2 grams of carbohydrates a day, a person about 250
A mouse eats about 2 grams of carbohydrates a day, a person about 250

Two grams versus 250

The biggest question about the device is arithmetic. In a lab test, the catalyst cleared nearly all the glucose from five liters of solution, roughly the total blood volume of an adult. But a body is not a flask. People eat all day.

David Klonoff, an endocrinologist at Sutter Mills-Peninsula Medical Center in California, was not involved in the study. He ran the numbers for Science News: an adult eats about 250 grams of carbohydrates a day, a mouse about two. A load like that could take a much larger implant, or several. Klonoff called the approach potentially promising, but said the risks are significant and must be carefully ruled out before anyone tests it in people.

Drugs already on pharmacy shelves give a sense of scale. Pills called SGLT2 inhibitors stop the kidneys from pulling glucose back into the blood, so it leaves in urine. In a 2014 study of 66 patients, one of them, empagliflozin, flushed out about 28 grams of glucose in the five hours after a meal. The implant works differently: it first turns glucose into another substance, and that is what the kidneys must clear. How much of it they can handle is far from a theoretical question.

Klonoff spells out the risks. Nobody knows how much gluconate the kidneys can clear safely. If it builds up, it could throw off the blood’s acid-base balance, causing nausea or confusion. And flushing it out could drain the body of sodium and potassium.

After years of designing ever cleverer switches for living cells, the lab finally has a device that is simple to build and holds nothing for the immune system to reject. The open question is whether a scrap of felt can scale up to a human’s daily carbohydrates without asking more of the kidneys than they can give.